BioSpace

Dren Bio lands $350M to push rare blood cancer therapy toward market

After Sanofi paid $600 million in cash to acquire Dren Bio’s bispecific last year, the biotech has secured a hefty financing to fund late-stage development and commercial preparations for its lead asset.

By BioSpace

1 min read
Dren Bio lands $350M to push rare blood cancer therapy toward market
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights